Driven by partnerships
Since 2018, Orphelia Pharma has been working in close collaboration with Gustave Roussy, one of the largest cancer centers in Europe, on developing a liquid oral formulation of temozolomide for neuroblastoma, a rare cancer affecting very young children.
Orphelia Pharma wishes to develop drugs addressing unmet medical needs. Join our research team and help us to identify the key medical needs and assess potential drug candidates.
Industrial partnerships are essential for the manufacturing of prototypes, pilot batches and clinical batches. Orphelia Pharma mainly works with French and European partners.
Marketing partnerships are set up to ensure our products are available to pediatric patients worldwide. Work with us through distribution agreements or licensing contracts to help bring vital treatments to more patients.